Datapoint: AstraZeneca, Daiichi Score Earlier Breast Cancer Use for Enhertu

The FDA on May 5 approved AstraZeneca and Daiichi Sankyo’s Enhertu for earlier use in metastatic, HER2+ breast cancer patients. The antibody treatment is currently approved as a third-line therapy, and can now be used as a second-line therapy in patients with recurring disease within six months of receiving a different HER2 inhibitor. As a breast cancer therapy, Enhertu currently holds covered or better status for 63% of all insured lives under the pharmacy benefit. Under the medical benefit, the drug holds 78% covered or better status.

SOURCE: MMIT Analytics, as of 5/11/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 23

Datapoint: Skyrizi Scores Crohn’s Disease Nod

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 22

Datapoint: Merck-Seagen Deal Could Be in the Works

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 21

Datapoint: Centene Settles New Mexico Medicaid Dispute

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today